OR WAIT null SECS
Click here to read the articles and download the PDF
A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.
Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.
Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.
December 15, 2023
Breakout session summarizes key areas that will affect all aspects of the industry.
Creating a meaningful digital transformation requires pharmaceutical manufacturing companies to incorporate the right technologies, processes, and systems to reach their fullest potential.
The FDA based the approval Merck’s Welireg (belzutifan) on findings from the randomized, open-label, Phase III LITESPARK-005 trial, which compared Welireg to Afinitor for the treatment of advanced RCC that has progressed after prior treatment with PD-1/L1 and VEGF-TKI therapies.
MoU aims to align the pharmaceutical and cold chain sectors by boosting operations.
December 14, 2023
Partner for Archbow Consulting discusses the conference, the IRA, and specifics of PAP business rules
Eflornithine (Iwilfin) is indicated to lower the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who showed at least a partial response to previous multi-agent and multimodality treatment that included an anti-GD2 immunotherapy.
Bill Trombetta, PhD, discusses successfully navigating what he calls “the coming perfect storm” in healthcare.
December 13, 2023
The conference hosts a diversity, equity, and inclusion (DE&I) Summit featuring personal insights and experiences.
Pfizer said that the addition of Seagen to its current operations could add more than $10 billion in risk-adjusted revenues by 2030.
MAPS Public Benefit Corporation was previously granted Breakthrough Therapy Designation by the FDA for MDMA and is seeking a priority review for the NDA submission of the psychedelic treatment for post-traumatic stress disorder.